SPYRE THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SPYRE THERAPEUTICS, INC. (SYRE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.49 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2018-03-13
- SPYRE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $2.49M, a 104.10% increase from fiscal 2016.
- SPYRE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $1.22M, a 63.45% increase from fiscal 2015.
- SPYRE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2015 was $747.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|
| 2017-12-31 | $2.49M 10-K · filed 2018-03-13 |
| 2016-12-31 | $1.22M 10-K · filed 2018-03-13 |
| 2015-12-31 | $747.00K 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |